Takehara T. Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. Am J Physiol Gastrointest Liver Physiol 301: G1031-G1043, 2011. First published September 1, 2011; doi:10.1152/ajpgi.00211.2011.-Recent studies indicate an accelerated progression of nonalcoholic steatohepatitis (NASH) in postmenopausal women. Hypercholesterolemia, an important risk factor for NASH progression, is often observed after menopause. This study examined the effects of estrogen on NASH in ovariectomized (OVX) mice fed a high-fat and high-cholesterol (HFHC) diet. To investigate the effects of estrogen deficiency, OVX mice and sham-operated (SO) mice were fed normal chow or HFHC diet for 6 wk. Next, to investigate the effects of exogenous estrogen replenishment, OVX mice fed with HFHC diet were treated with implanted hormone release pellets (containing 17␤-estradiol or placebo vehicle) for 6 wk. OVX mice on the HFHC diet showed enhanced liver injury with increased liver macrophage infiltration and elevated serum cholesterol levels compared with SO-HFHC mice. Hepatocyte monocyte chemoattractant protein-1 (MCP1) protein expression in OVX-HFHC mice was also enhanced compared with SO-HFHC mice. In addition, hepatic inflammatory gene expressions, including monocytes chemokine (C-C motif) receptor 2 (CCR2), were significantly elevated in OVX-HFHC mice. Estrogen treatment improved serum cholesterol levels, liver injury, macrophage infiltration, and inflammatory gene expressions in OVX-HFHC mice. Moreover, the elevated expression of liver CCR2 and MCP1 were decreased by estrogen treatment in OVX-HFHC mice, whereas low-density lipoprotein dose dependently enhanced CCR2 expression in THP1 monocytes. Our study demonstrated that estrogen deficiency accelerated NASH progression in OVX mice fed HFHC diet and that this effect was improved by estrogen therapy. Hypercholesterolemia in postmenopausal women would be a potential risk factor for NASH progression. nonalcoholic steatohepatitis/nonalcoholic fatty liver disease, postmenopause NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) describes a broad spectrum of liver disorders ranging from benign simple steatosis to nonalcoholic steatohepatitis (NASH). NAFLD/NASH is considered the hepatic manifestation of the metabolic syndrome (Mets) and represents a growing medical problem in Western countries that is closely associated with obesity, insulin resistance, hypertension, and dyslipidemia (5, 40). The prevalence and severity of NASH reportedly differ with sex, with females showing an acceleration of disease progression after menopause (44, 52) . Postmenopausal women also show a markedly accelerated accumulation of visceral fat and a rapid increase in the prevalence of Mets (27, 31). Moreover, the progression of atherosclerosis and dyslipidemia increases after menopause but can be improved by estrogen administration (17, 35). These findings implicate an important role for estrogen in the pathophysiology of NAFLD/NASH. Estrogen controls energy homeostasis by regulating mitochondrial function (12). In aromatase knockout mice, which cannot synthesize endogenous estrogens, hepatic steatosis arises spontaneously in these mice due to the impaired hepatic fatty acid ␤-oxidation (38). The impairment in mitochondrial and peroxisomal fatty acid ␤-oxidation can be restored by estrogen supplementation in these mice (38). Compound heterozygous mutation of the aromatase gene in an adult humans presented as Mets characterized by abdominal obesity and NAFLD (32). Similarly, estrogen receptor (ER)-␣ knockout mice had hepatic steatosis (15, 30). Moreover, progressive hepatic steatosis among nonobese and nondiabetic patients with breast cancer treated with tamoxifen, a potent estrogen antagonist, induced NASH (39, 41). Thus estrogen deficiency could induce and exacerbate NAFLD/NASH progression in both human and mice.
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Recent studies indicate that dietary cholesterol is an important risk factor for the progression of NASH in both human and rodents (34, 36, 50, 51) and that hypercholesterolemia and serum low-density lipoprotein (LDL) levels are independent predictors of human NASH severity (45) . Lipidomic analysis indicated that hepatic free cholesterol content increased progressively from normal controls to patients with simple steatosis to NASH (42) . Moreover, cholesterol-lowering drugs, such as statins and ezetimibe, demonstrably slowed NASH progression (1, 9, 19, 24) . In the absence of estrogen action, mice developed progressive obesity and hypercholesterolemia (15, 16) . Hypercholesterolemia and elevated serum LDL levels are also observed in postmenopausal women, and estrogen administration results in lowered serum levels of cholesterol and LDL (6, 17, 37) .
Considering these findings, the estrogen deficiency itself and estrogen deficiency-induced hypercholesterolemia should accelerate the severity of NASH in postmenopausal women. However, the precise mechanisms underlying this progression are still unclear. To address this issue, we investigated the effects of estrogen on NASH progression in ovariectomized (OVX) mice fed high-fat and high-cholesterol (HFHC) diet.
MATERIALS AND METHODS
Experimental protocol. All experimental protocols and animal maintenance procedures used in this study were approved by the Ethics Review Committee for Animal Experimentation of Osaka University Graduate School of Medicine. Female C57BL/6J mice were purchased from Clea Japan (Tokyo, Japan) and maintained for 1 wk under the same conditions before starting the experiments. The animals were provided with unrestricted amounts of chow and water, housed in temperature-and humidity-controlled rooms, and maintained on a 12-h:12-h light/dark cycle. The HFHC diet (containing 1.25% cholesterol, 15% cocoa butter, and 0.5% cholic acid) was purchased from Oriental Yeast (Suita, Osaka, Japan).
To investigate the effects of estrogen deficiency, 28 female C57BL/6J mice (10-wk-old) were used. All mice were anesthetized for surgery, and either a bilateral ovariectomy (n ϭ 14) or sham operation (SO) (n ϭ 14) was performed. One week after the surgery, mice were divided into four groups (n ϭ 7 for each groups) and fed with normal chow (NC) or the HFHC diet for 6 wk (SO-NC group, SO-HFHC group, OVX-NC group, OVX-HFHC group). SO mice fed with NC diet (n ϭ 7) served as controls.
We next investigated the effects of exogenous estrogen replenishment, with the use of 12 OVX mice divided into two groups. All mice were implanted subcutaneously with 60-day release hormone pellets (Innovative Research of America, Toledo, OH) that contained 0.5 mg 17␤-estradiol (E2) (n ϭ 6) or placebo vehicle alone (n ϭ 6). This estradiol dosage was shown to yield serum estrogen concentrations within the physiological range (46) . One week after surgery, mice were fed for 6 wk on the HFHC diet [OVX-HFHC group (n ϭ 6), OVX-HFHCϩE2 group (n ϭ 6)].
At the end of the each experimental period, mice were fasted overnight (10:00 PM-8:00 AM) but had free access to water and then euthanized after being weighed. Blood was collected aseptically from the inferior vena cava, centrifuged (13,000 g, 5 min, 4°C), and serum was collected. Mice spleens were harvested for isolating monocytes. The livers were also harvested and either fixed with 10% buffered formaldehyde for histological examination or immediately frozen in liquid nitrogen for mRNA extraction and lipid analysis. Hematoxylineosin staining of mice liver specimens was performed according to standard techniques. Samples were investigated and quantified according to NAFLD activity scoring (NAS) (25) . Steatosis (0 -3), lobular inflammation (0 -2), and hepatocellular ballooning (0 -2) were quantified, respectively.
Measurements of serum biochemical markers and liver lipid content. Serum alanine aminotransferase (ALT), glucose, and insulin concentrations were measured using the transaminase CII-test kit, glucose CII-test kit (Wako Pure Chemical Industries, Tokyo, Japan), and insulin ELISA kit (Morinaga, Yokohama, Japan), respectively, according to the manufacturers' instructions. Insulin resistance was calculated according to the homeostasis model of assessment of insulin resistance (HOMA-IR) using the formula, insulin (U/ml) ϫ blood glucose (mmol/l)/22.5.
Total lipids were extracted from the liver as described previously (22) . Serum and liver triglyceride (TG), total cholesterol, and free fatty acid (FFA) were measured using the TG E-test kit, cholesterol E-test kit (Wako Pure Chemical Industries), and NESCAUTO NEFA Kit-U (Alfresa-Pharma, Osaka, Japan), respectively, according to the manufacturers' instructions. Serum lipoproteins were analyzed using an online dual-enzymatic method for the simultaneous quantification of cholesterol and TG using high-performance liquid chromatography (HPLC) at Skylight Biotech (Akita, Japan), according to a procedure described previously (49) .
Mice hepatic gene expression analysis and quantitative RT-PCR. Forty-seven genes with links to NAFLD pathophysiology (cholesterol metabolism, endoplasmic reticulum stress, fatty acid metabolism, glucose metabolism, inflammation, macrophage, nuclear receptor) were chosen for analysis on a custom-made TaqMan Array Plate (Applied Biosystems, Foster City, CA). Total RNA was extracted from whole liver with the QIAshredder and the RNeasy Mini kit according to the instructions provided by the manufacturer (Qiagen, Hilden, Germany). Complementary DNAs (cDNAs) were reverse transcribed from total liver RNA samples using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) from SO-NC, SO-HFHC, OVX-NC, and OVX-HFHC mice liver. The cDNA of each mice group was mixed, and per individual assay 10 ng cDNA of each group mice liver was loaded together with TaqMan Gene Expression Master Mix (Applied Biosystems) and applied to single wells in a 96-well TaqMan Array Plate. This assay was performed on the Applied Biosystems 7900HT RT-PCR system (Applied Biosystems). Data were normalized to 18S expression.
Total RNA was extracted from whole liver or cells with the QIAshredder and RNeasy Mini kit according to the instructions provided by the manufacturer. The RNA was then transcribed into cDNA using a Quantitect Reverse Transcription kit (Qiagen, Hilden, Germany). Quantitative real-time PCR was performed with the QuantiFast SYBR Green PCR kit using specific primers (Qiagen) on a LightCycler according to the instructions provided by the manufacturer (Roche Diagnostics, Indianapolis, IN). The primers used in this study were all purchased from Qiagen [monocyte chemoattractant protein-1 (MCP1) (QT00167832), monocytes chemokine (C-C motif) receptor 2 (CCR2) (QT02276813), TNF-␣ (QT00104006), IFN-␥ (QT01038821), IL12 (QT01048334), nitric oxide synthase-2 (NOS2) (QT00100275), IL10 (QT00106169), IL4 (QT00160678), transforming growth factor-␤1 (TGF-␤1) (QT00145250), collagen I␣1 (QT00162204), cholesterol 7␣-hydroxylase (CYP7A1) (QT00121569), LDL receptor (LDLR) (QT00109823), 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) (QT01037848), CD36 (QT01058253), and GAPDH (QT00199388)]. The mRNA expression levels were normalized relative to GAPDH mRNA expression levels and expressed in arbitrary units. Picrosirius red staining and immunohistochemistry. Picrosirius red (Sigma, St. Louis, MO) staining was used to detect collagen fibrils in mice specimens. The fibrosis area stained by picrosirius red in this study was quantified by using Adobe Photoshop (Adobe Systems, San Jose, CA) as described previously (23) .
Mice liver tissue sections were subjected to immunohistochemical staining using a monoclonal antibody against rat anti-mouse F4/80 (1:100) (Serotec, Oxford, UK) or MCP1 (1:250) (Cell Signaling, Beverly, MA).
CCR2 expression in monocytes. Monocytes were isolated from mice spleens of each group by magnetic cell sorting using magnetic beads (MACS; Miltenyi Biotec, Gladbach, Germany) with CD11b antibody according to the manufacturer's protocol. RNA was extracted from the spleen monocytes of mice from each group for quantitative real-time RT-PCR analysis. THP1 cells, a human monocytic cell line, were obtained from American Type Culture Collection (ATCC) (Manassas, VA). Growth medium consisted of RPMI-1640/ 10% FCS. To examine the effect of LDL (Sigma) on monocyte CCR2 expression, THP1 monocytes were cultured in RPMI medium with or without individual concentrations of LDL (0, 5, 50 g/ml) for 18 h, and RNA was extracted for quantitative real-time RT-PCR analysis.
Statistical analysis. Statistical analysis was conducted using JMP 8.0 software (SAS Institute, Cary, NC). The results are presented as means Ϯ SD. Differences between groups were examined for statistical significance using ANOVA with Fisher's paired least-significant difference test. Statistical significance was defined as P Ͻ 0.05.
RESULTS

Ovariectomy enhances liver injury in HFHC diet-fed mice.
Body weight was significantly elevated in OVX-NC mice compared with SO-NC mice (Table 1) . Liver weight was significantly higher in OVX-HFHC mice than in SO-HFHC mice, whereas epididymal fat weight was significantly higher in OVX mice than in SO mice with both NC and HFHC diet feeding. Serum ALT and cholesterol levels were significantly increased in OVX-HFHC mice compared with SO-HFHC mice, whereas liver TG levels were decreased in OVX-HFHC mice compared with SO-HFHC controls, and liver cholesterol contents were elevated in HFHC diet-fed mice compared with NC diet-fed mice with or without ovariectomy. There were no differences in liver cholesterol contents between the HFHC groups.
There were no changes in liver histology between SO and OVX mice on NC diets (Fig. 1A) . In HFHC diet-fed mice, ovariectomy significantly increased the numbers of infiltrating inflammatory cells in liver. We next assessed the NAS in the mice livers (Fig. 1B) . The liver steatosis score was increased in HFHC diet-fed mice compared with those fed an NC diet, but there was no change in hepatic steatosis between the HFHC diet-fed groups. However, both lobular inflammation and hepatocyte ballooning scores were significantly elevated in OVX-HFHC mice compared with SO-HFHC mice. Consequently, the total NAS was significantly higher in OVX-HFHC mice than in SO-HFHC mice, as were serum ALT levels (Fig. 1C) .
Impact of ovariectomy and diet on serum lipoprotein and cholesterol levels. To investigate whether dyslipidemia was induced by ovariectomy, we checked serum lipoprotein and cholesterol levels in the mice (Fig. 2, A-C) . Cholesterol lipoprotein distribution by HPLC showed that HFHC diet feeding elevated serum very-low-density lipoprotein (VLDL) and LDL cholesterol levels in SO-HFHC mice compared with SO-NC mice, and this increase was exacerbated in the OVX-HFHC mice. In contrast, high-density lipoprotein (HDL) cholesterol levels were decreased in HFHC diet-fed mice. Serum total cholesterol levels were also increased in SO-HFHC mice compared with SO-NC mice and further increased in OVX-HFHC mice. A consistent finding was increased serum cholesterol levels in the mice that developed hepatic inflammation, suggesting that serum total cholesterol level is an important determinant of hepatic inflammation. As expected, serum total cholesterol levels and serum ALT levels were significantly correlated in this study. 
Changes in macrophage infiltration and hepatic inflammatory gene expression are enhanced in OVX-HFHC mice liver.
To investigate the mechanism of accelerated steatohepatitis in the OVX-HFHC mice, we analyzed the expressions of 47 genes associated with NAFLD pathophysiology using a TaqMan Array Plate (Tables 2 and 3 ). The gene expression of CYP7A1, a rate-limiting enzyme in bile acid production from cholesterol, was significantly decreased in OVX mice liver compared with SO-NC and SO-HFHC mice (Fig. 2D) . The gene expression of HMGCR was decreased in OVX-HFHC mice compared with SO-HFHC mice, but there were no significant differences in the gene expression of LDLR among mice groups. CD36, a major scavenger receptor, was downregulated in the liver of OVX-HFHC mice compared with SO-HFHC mice. There were no obvious expression changes in other genes related to cholesterol metabolism, fatty acid metabolism, glucose metabolism, or nuclear receptors between the HFHC diet-fed groups (Table 2 ). However, genes related to inflammation and macrophage infiltration were highly upregulated in OVX-HFHC mice compared with SO-HFHC mice, including TNF-␣, MCP1, CCR2, F4/80, and NOS2 (Table 3) .
Gene expression profiling indicated enhanced inflammatory macrophage infiltration in OVX-HFHC mice livers. We therefore assessed liver macrophage infiltration using F4/80 immunohistochemistry (Fig. 3A) . In NC diet-fed mice, the degree of liver macrophage infiltration was not different with or without ovariectomy. In contrast, massive macrophage infiltration was seen in OVX-HFHC mice liver.
To examine the expressions of inflammatory cytokines and chemokines, we performed quantitative real-time RT-PCR (Fig. 3B) . The gene expressions of hepatic MCP1 and its receptor CCR2 were significantly elevated in OVX-HFHC mice compared with SO-HFHC mice. Inflammatory cytokine genes for TNF-␣, IFN-␥, and NOS2 were also significantly upregulated in OVX-HFHC mice livers. In contrast, there were no obvious changes in anti-inflammatory Th2 cytokine expressions, including IL10 and IL4.
We next assessed the relationships between mice serum cholesterol levels and hepatic inflammatory gene expressions levels (Fig. 3C) . Interestingly, the expression of all the relevant factors (MCP1, CCR2, TNF-␣, IFN-␥, IL12, and NOS2) correlated significantly with serum cholesterol levels.
Higher hepatic MCP1 protein expression in OVX-HFHC mice than SO-HFHC mice. It was previously reported that dietary cholesterol enhances hepatic MCP1 expression (48) , and hepatic MCP1 gene expression was elevated in the OVX-HFHC mice in this study. Accordingly, we also examined the levels of hepatic MCP1 protein expression in mice using immunohistochemistry (Fig. 3D ). There were no differences in liver MCP1 staining in NC-fed mice with or without ovariectomy. HFHC diet feeding increased the number of MCP1-positive hepatocytes, and this number was further increased in OVX-HFHC mice.
Enhanced liver fibrosis in OVX-HFHC mice compared with SO-HFHC mice. Picrosirius red staining revealed increased hepatic fibrosis in OVX-HFHC mice (Fig. 4) . The expressions of fibrogenic genes, TGF-␤1 and collagen I␣1, were also increased in SO-HFHC mice compared with SO-NC mice and further increased in OVX-HFHC mice. In addition, the gene expressions levels of TGF-␤1 and collagen I␣1 were significantly correlated with serum cholesterol levels.
Administration of estrogen ameliorates liver injury in OVX-HFHC mice.
To investigate the therapeutic effects of estrogen following ovariectomy, we next investigated another set of OVX-HFHC mice implanted with estrogen pellets (OVX-HFHCϩE2). Body weight was significantly decreased in OVX-HFHCϩE2 mice compared with OVX-HFHC controls (Table 4 and Fig. 5 ), whereas liver weight was not different. In addition, epididymal fat weight, serum ALT level, and serum cholesterol level (total as well as VLDL and LDL cholesterol) were significantly decreased in OVX-HFHCϩE2 mice compared with OVX-HFHC mice. Serum cholesterol levels in these groups of mice correlated significantly with serum ALT levels (Fig. 6 ). There were no significant changes in liver lipid contents. Assessment of liver histology using NAS revealed that estrogen ameliorated the liver inflammation and hepatocyte ballooning in treated mice compared with OVX-HFHC mice. F4/80 immunohistochemistry revealed that both estrogen treatment decreased the hepatic macrophage infiltration observed in OVX-HFHC mice (Fig. 7A) , with a concomitant downregulation of hepatic inflammatory gene expressions compared with untreated OVX HFHC mice (Fig. 7B) . Hepatic gene expressions of CYP7A1 and LDLR were elevated in mice after estrogen treatment compared with OVX-HFHC mice (Fig. 6D) . Hepatic HMGCR gene expression was higher in OVX-HFHCϩE2 mice than OVX-HFHC mice. The levels of hepatic inflammatory genes, MCP1, CCR2, TNF-␣, IFN-␥, and NOS2, were significantly decreased with the reduction in serum cholesterol levels in mice treated with estrogen (Fig. 7C) . MCP1 immunohistochemistry revealed that estrogen treatment decreased hepatocyte MCP1 expression in OVX HFHC mice liver (Fig. 7D) . Picrosirius red staining revealed that estrogen treatment improved liver fibrosis in OVX-HFHC mice (Fig. 8) . The gene expression of liver collagen I␣1 was also improved by estrogen treatment, but hepatic TGF-␤1 expression showed no changes. Hepatic collagen I␣1 gene expression decreased in accordance with the reduction in serum cholesterol although there was no statistical correlation between mice liver TGF-␤1 and serum cholesterol levels.
Cholesterol loading induces monocyte CCR2 gene expression. We examined CCR2 gene expression in mice spleen monocytes from all five groups in this study (Fig. 8D) . HFHC diet feeding elevated CCR2 expression in SO-HFHC mice compared with SO-NC mice, and ovariectomy further increased the CCR2 expression in OVX-HFHC mice. This CCR2 upregulation was in turn ameliorated by estrogen treatment. These changes in monocyte CCR2 expression were similar to the changes in serum cholesterol concentrations, which is consistent with previous studies that showed marked increase in monocyte CCR2 expression in hypercholesterolemic patients, and LDL loading resulted in increased monocyte CCR2 expression (13, 14) . We also found that LDL dose dependently increased the CCR2 expression in THP1 monocytes, one of the human monocyte cell lines (Fig. 8E) . These data could indicate that elevated serum cholesterol in OVX-HFHC mice induced monocyte CCR2 expression, leading to enhanced hepatic macrophage infiltration.
DISCUSSION
Recent studies have demonstrated accelerated progression of both NASH and hypercholesterolemia after menopause. Here, we showed that ovariectomy enhanced NASH progression with increased hepatic macrophage infiltrations in mice fed HFHC diet. Serum cholesterol levels were higher in OVX-HFHC mice than in SO-HFHC mice, and serum cholesterol levels significantly correlated with serum ALT levels, liver injury, and changes in the expression levels of various hepatic inflammatory genes. Estrogen replenishment decreased serum cholesterol levels and attenuated liver injury in HFHC diet-fed mice. Moreover, hepatic MCP1 protein expression was significantly increased in OVX-HFHC mice compared with SO-HFHC mice, and this effect was rescued by estrogen treatment. In an in vitro study, LDL dose dependently upregulated the gene expression of CCR2, known as the MCP1 receptor, in THP1 monocytes. These results indicated that estrogen deficiency enhanced NASH progression through increased hepatic macrophage infiltration in mice fed with HFHC diet. Hypercholesterolemia in postmenopausal women should accelerate NASH progression, suggesting that treatment of hypercholesterolemia would improve NASH pathophysiology in women after menopause.
Dyslipidemia is commonly observed in NASH patients, and it has been postulated that abnormalities in lipid metabolism, such as increased serum LDL cholesterol levels and decreased HDL cholesterol levels, may be contributing factors to NASH development (26) . Accordingly, hyperlipidemic mice develop diet-induced NASH, including not only LDLR knockout mice, but also apolipoprotein E-deficient mice (50, 53) . Unlike humans, mice fed an NC diet carry most of their lipids as HDL. However, mice fed an HFHC diet adopt a human-like lipoprotein profile and thus could serve as a useful physiological animal model to study the progression of NASH.
Cholesterol homeostasis is mainly achieved by regulating the enzymes involved in cholesterol synthesis, uptake, and clearance (3), and estrogen plays important roles in regulating cholesterol homeostasis. For example, estrogen stimulates expression of the LDLR gene through the ER-␣, which can activate transcription of the LDLR promoter through Sp1 interaction (4) . The HMGCR promoter also has an estrogenresponsive element-like sequence, and estradiol stimulates HMGCR activity (10) . In this study, LDLR gene expression did not change, HMGCR gene expression was reduced in OVX-HFHC mice compared with SO-HFHC mice, and estrogen supplementation elevated both gene expressions in mice liver. Hepatic cholesterol levels were similar despite the higher serum cholesterol levels between the HFHC mice groups, which might reflect a reduced liver cholesterol uptake by LDLR and a reduced hepatic de novo cholesterol production by HMGCR. In addition, the cholesterol clearance rate would be interrupted in the estrogen-deficient state (16) . CYP7A1 catalyzes the rate-limiting step of cholesterol conversion into bile acid and is encoded by the CYP7A1 gene. Estrogen administration increased CYP7A1 activity in baboon in vivo, and estradiol upregulated CYP7A1 gene expression in rat hepatocytes in vitro (8, 28) . Aromatase knockout mice, which cannot synthesize endogenous estrogen and present age-progressive obesity and hepatic steatosis, develop hypercholesterolemia (16) . These mice show significantly reduced hepatic CYP7A1 expression compared with wild-type mice, and the reduced cholesterol clearance attributable to the decreased CYP7A1 activity increased serum cholesterol levels. In our study, hepatic CYP7A1 gene expression was also decreased in OVX mice as expected, and estrogen treatment restored this hepatic expression. The interrupted cholesterol clearance in OVX mice should therefore induce enhanced hypercholesterolemia in the HFHC mice in our study.
Recent studies point to the importance of dietary cholesterol as a toxic lipid in liver inflammation and NASH both in rodents and humans (33, 34, 36, 48, 50, 51) . Mari et al. (33) reported that high-cholesterol feeding causes lipotoxicity that sensitizes rat livers to develop hepatic inflammation after exposure to TNF or fatty acid synthase. In addition, dietary cholesterol induced hepatic MCP1 gene expression (48) , and monocyte CCR2 expression was increased in hypercholesterolemic patients compared with normocholesterolemic controls (14) . Cholesterol directly stimulates the CCR2 promoter activity through its cholesterol response element (7, 14) , and, in this study, elevated serum cholesterol in OVX-HFHC mice increased, not only hepatocyte MCP1 expression, but also monocyte CCR2 expression in mice. Enhanced MCP1 expression in mice liver recruited CCR2-positive monocytes into the liver, and these recruited monocytes transformed into inflammatory macrophages.
The accumulation of macrophages at sites of inflammation and injury in the liver is thought to be mediated by chemokines such as MCP1. Accumulated inflammatory macrophages in mice liver produce various inflammatory cytokines, such as TNF-␣ and IFN-␥, leading to persistent liver injury. Estrogen at physiological concentrations inhibits the spontaneous secretion of these inflammatory cytokines in whole blood cultures (43) . Moreover, hydrogen peroxide-induced TNF-␣ and MCP1 expressions were attenuated by estradiol in peritoneal macrophages from female mice (18) , whereas estrogen inhibited MCP1 expression in human endometrial stromal cells, and tamoxifen, an estrogen antagonist, reversed the inhibition of MCP1 by estrogen (2) . Finally, estrogen significantly decreased mice monocyte CCR2 expression and decreased chemotaxis of monocytes toward MCP1 (21) . These findings suggest that estrogen itself may have hepatoprotection against inflammation by preventing macrophage accumulation and inhibiting proinflammatory cytokine production.
Estrogen has both anti-inflammatory and antifibrotic effects in the liver. During liver fibrogenesis, hepatic stellate cells (HSC) play a central role (11) . HSC possess functional ER-␤, but not ER-␣, to respond directly to estrogen exposure. In addition, estrogen prevented reactive oxygen species and TGF-␤ production in cultured rat HSC by suppressing NADH/ NADPH oxidase activity (20) . In our study, fibrogenic genes, TGF-␤1 and collagen I␣1, were upregulated in OVX-HFHC mice, and estrogen treatment improved the hepatic collagen I␣1 expression.
NASH is reported to be correlated with atherosclerotic cardiovascular diseases independently of Mets (47) . In this study, we used HFHC diet (containing 15% cocoa butter, 1.25% cholesterol, and 0.5% cholate) to induce steatohepatitis in mice. This diet is known to be an atherogenic diet. This HFHC diet is also known to induce liver steatosis, inflammation, and fibrosis (34) . This model seems to be a more physiological dietary model of NASH than existing animal models, which require genetic defects or the depletion of nutrients, such as methionine and choline deficiency diet-induced model. Moreover, the liver pathology induced by HFHC diet feeding involves steatohepatitis with hepatocellular ballooning, a necessary histological feature defining human NASH. These results indicate that the HFHC diet-induced NASH model in mice is one of the better experimental models of human NASH.
It was reported that mice fed HFHC diet were smaller than control mice, and insulin sensitivity and glucose tolerance were similar between HFHC-fed mice and NC diet-fed mice (29, 34) . However, hepatic insulin resistance, as assessed by the liver insulin receptor substrate-2 (IRS-2) expression, was increased in HFHC-fed mice (34) . In this study, both body weight and insulin resistance, as assessed by HOMA-IR, in HFHC diet-fed mice did not increase compared with in NC diet-fed mice, and IRS-2 gene expression was decreased in HFHC diet-fed mice liver (Table 2 ). These results indicated that hepatic insulin resistance would exist in HFHC-fed mice in our study.
In conclusion, our study demonstrated that estrogen deficiency promoted NASH progression and that estrogen treatment improved NASH progression in mice fed HFHC diet. Extrapolation of our results into the clinical setting suggests that estrogen deficiency and estrogen deficiency-induced hypercholesterolemia in postmenopausal women could potentially exacerbate NASH progression through enhanced liver inflammatory macrophage infiltration.
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